ADMA Biologics (ADMA) Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Do institutionals and insiders hold more shares of ACAD or ADMA?

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has better valuation and earnings, ACAD or ADMA?

ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$957.80M	3.68	$226.45M	$1.33	15.71
ADMA Biologics	$426.45M	8.04	$197.67M	$0.86	16.70

Does the media refer more to ACAD or ADMA?

In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than ADMA Biologics. MarketBeat recorded 8 mentions for ACADIA Pharmaceuticals and 6 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.99 beat ACADIA Pharmaceuticals' score of 0.24 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, ACAD or ADMA?

ACADIA Pharmaceuticals has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.

Is ACAD or ADMA more profitable?

ADMA Biologics has a net margin of 44.06% compared to ACADIA Pharmaceuticals' net margin of 21.80%. ADMA Biologics' return on equity of 41.01% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	21.80%	14.69%	9.41%
ADMA Biologics	44.06%	41.01%	28.47%

Do analysts prefer ACAD or ADMA?

ACADIA Pharmaceuticals currently has a consensus target price of $29.12, suggesting a potential upside of 39.39%. ADMA Biologics has a consensus target price of $27.67, suggesting a potential upside of 92.66%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Summary

ACADIA Pharmaceuticals and ADMA Biologics tied by winning 8 of the 16 factors compared between the two stocks.